BRIEF published on 12/19/2025 at 12:05, 7 months 15 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 7 months 15 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 8 months 20 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 8 months 20 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 8 months 26 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 8 months 26 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 9 months 11 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 9 months 11 days ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 9 months 25 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 9 months 25 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
Published on 08/03/2026 at 23:00, 9 hours 56 minutes ago Viemed Healthcare Announces Second Quarter 2026 Financial Results
Published on 08/01/2026 at 01:20, 3 days 7 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 3 days 7 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 3 days 8 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/04/2026 at 08:30, 26 minutes ago Mutares grows and generates Group revenues of EUR 3.4 billion in the first half of 2026 – further exit activities expected in the second half, guidance for fiscal year 2026 confirmed
Published on 08/04/2026 at 08:20, 36 minutes ago Mutares completes landmark acquisition of the Engineering Thermoplastics Business in the Americas and Europe from SABIC
Published on 08/04/2026 at 08:00, 56 minutes ago Genel Energy PLC: Unaudited results for the period ended 30 June 2026
Published on 08/04/2026 at 08:00, 56 minutes ago Metro Bank Holdings PLC: Results for the half year ended 30 June 2026
Published on 08/04/2026 at 08:15, 41 minutes ago Covivio - Conditions of availability of the 2026 Half-year report
Published on 08/03/2026 at 18:45, 14 hours 11 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 17:45, 15 hours 11 minutes ago Monthly disclosure of the total number of shares and voting rights - July 2026
